Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117495 | 0.81 | POLB (0.38) | GRIK1GRIK2CYP2C19CPA1LMNA | |
| SCHEMBL20201445 | 0.78 | GRIK1 (0.38) | GRIK1GRIK2CYP2C19CPA1FOLH1 | |
| SCHEMBL6579012 | 0.75 | LMNA (0.38) | CYP2C19LMNAFOLH1 | |
| SCHEMBL9229673 | 0.75 | FOLH1 (0.48) | GRIK1GRIK2CYP2C19CPA1LMNA | |
| SCHEMBL10875658 | 0.74 | FOLH1 (0.38) | CYP2C19LMNAFOLH1 | |
| SCHEMBL3899260 | 0.72 | CHRM1 (0.43) | GRIK1GRIK2CYP2C19LMNAFOLH1 | |
| SCHEMBL9184149 | 0.72 | FOLH1 (0.36) | CYP2C19LMNAFOLH1 | |
| SCHEMBL9181835 | 0.71 | FOLH1 (0.59) | GRIK1GRIK2FOLH1 | |
| SCHEMBL787792 | 0.69 | CA2 (0.44) | LMNA | |
| SCHEMBL15951729 | 0.69 | GRIK1 (0.35) | GRIK1GRIK2CYP2C19LMNAFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | GRIK1 2154/4885GRIK2 2963/4885CYP2C19 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.